Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes
Summary Dupilumab reduces tissue eosinophils in nasal polyps beyond improving clinical and endoscopic outcomes. Dupilumab treatment is associated with a reduction of tissue inflammatory eosinophils that correlates with higher clinical and endoscopic improvement.
Authors
- A Matucci
- Annarita Palomba (ORCID: https://orcid.org/0000-0001-5082-5041)
- Matteo Accinno
- Carlo Ammatuna
- Giandomenico Maggiore (ORCID: https://orcid.org/0000-0002-2741-4460)
- Emanuele Vivarelli (ORCID: https://orcid.org/0000-0001-5955-5076)
- Michael Diomaiuti
- Gennaro Illiano
- Alessandra Vultaggio
- Oliviero Rossi
- Pietro Orlando (ORCID: https://orcid.org/0000-0002-2372-2407)
- Enrico Maggi
- Lorenzo Cosmi
- Maria Elena Milanese
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Florence (IT)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1111/cea.70309
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00